Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

RECRUITING

Real World Evidence Clinical Utility Study of KidneyIntelX

NCT04802395 · View on ClinicalTrials.gov ↗

Study Summary

The purpose of this study is to assess the impact of the KidneyIntelX assay utilized as part of the current standard of care on the management of patients seen in the primary care physician's office at Mount Sinai.

Interventions

  • DIAGNOSTIC_TEST KidneyIntelX

Study Locations (1)

New York

  • Mount Sinai Health System — New York

Trial Details

FieldValue
Enrollment Target 10,000 participants
Start Date 2021-03-02
Est. Completion 2026-12-01

Sponsor

Renalytix AI

4 total trials

Interested in This Trial?

Always speak with your doctor before enrolling in a clinical trial.

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT04802395

The ClinicalTrials.gov registry entry for NCT04802395 describes a study currently listed as recruiting. It is categorized as an unspecified phase, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 10,000 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Renalytix AI, which has 4 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.

The record links to 2 conditions, with Chronic Kidney Diseases appearing as the primary indexed condition, and to 1 intervention — of which KidneyIntelX is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.

Geographic footprint matters for practical reasons: NCT04802395 reports 1 study location spanning 1 distinct geographic area — top geographies include New York. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.

Frequently Asked Questions

What is clinical trial NCT04802395 about?

NCT04802395 is a clinical study titled "Real World Evidence Clinical Utility Study of KidneyIntelX". The purpose of this study is to assess the impact of the KidneyIntelX assay utilized as part of the current standard of care on the management of patients seen in the primary care physician's office at Mount Sinai.

What is the current status of trial NCT04802395?

This trial is currently recruiting. The enrollment target is 10,000 participants. The study started on 2021-03-02. Estimated completion is 2026-12-01.

What conditions does trial NCT04802395 study?

This clinical trial studies the following conditions: Chronic Kidney Diseases, Diabetic Kidney Disease. These conditions were identified from the trial registry and reflect the primary focus areas of the research.

What interventions are being tested in trial NCT04802395?

The interventions under investigation include: KidneyIntelX (DIAGNOSTIC_TEST). Each intervention is being evaluated for safety and efficacy as part of this clinical study.

Who is sponsoring clinical trial NCT04802395?

This trial is sponsored by Renalytix AI, which has 4 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.

Where is trial NCT04802395 being conducted?

This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Related

Data sourced from official U.S. government datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial